



Sustiva® (efavirenz) – First-time generic

- On January 30, 2018, Mylan launched an [AB-rated](#) generic of Bristol-Myers Squibb's [Sustiva \(efavirenz\)](#) 600 mg tablets.
 - Mylan was granted 180 days of market exclusivity.
- Sustiva is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.
- Sustiva is also generically available as [capsules](#).



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.